Myasthenia gravis

Myasthenia gravis

Dora conteh mansary

Path

Dr. Isabelle Tardif

07/15/2018
Myasthenia gravis
2

Myasthenia Gravis an autoimmune neuromuscular disease. The condition is caused by a

breakdown in communication between nerves and muscles. The nerve endings release a

neurotransmitter called acetylcholine and the antibodies alters its connections to its receptors

. This causes abnormal fatigability which leads to weakness in the muscles and other

symptoms like trouble swallowing and eye impairments. In Longo article he presents and also

goes into the crisis of Myasthenia, and future directions

Longo address the many factors of making a prognosis in a patient exhibiting symptoms of

myasthenia gravis “Increasing generalized weakness, respiratory dysfunction, cardiac

dysfunction, severe infection, and coexisting conditions are all relevant factors to consider in

making this decision”. ( longo). He explains that the threshold of admitting patients into icu.

A simple approach measures the relative binding affinities of purified antibodies or T cell

receptors for different antigens. “Although the disease-inducing antibodies have been

characterized in detail, the treatment is far from immune specific” (Longo). Constructed
Myasthenia gravis
3

treatment Individuals is challenging even with today's advances Longo said. I agree with Long

that Implementing best-practice standards universally would present and challgen in

consistency

Reference page

Longo, D. L., & Gilhus, N. E. (2016). Myasthenia gravis. The New England Journal of Medicine, 375(26), 2570-

2581.